#United States #Dover #Eilean Therapeutics #CDK2 Inhibitor #CCNE1 Cancers

Eilean Therapeutics Unveils a New CDK2 Inhibitor

On October 16, 2025, Eilean Therapeutics LLC, a biopharmaceutical firm dedicated to advancing superior cancer therapies, revealed insightful preclinical findings regarding its innovative CDK2 inhibitor. This breakthrough was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

About the New CDK2 Inhibitor

The newly developed compound has demonstrated a remarkable selectivity for CDK2 in comparison with other cyclin-dependent kinases. Preliminary studies highlight its outstanding safety profile and broad therapeutic window. Particularly noteworthy is its potential in treating cancers that depend on cyclin-E1 (CCNE1) and display minimal responses to existing treatment regimens, including current CDK4/6 inhibitors.

According to Dr. Nikolay Savchuk, COO of Eilean Therapeutics, targeting CCNE1/CDK2-driven cancers is a critical unmet medical need. The data indicate that this compound strikes an optimal balance between potency, selectivity, and permeability to the brain, reinforcing its potential to assist patients afflicted with aggressive, resistant solid tumors.

Future Steps

Eilean Therapeutics plans to transition this promising CDK2 inhibitor into a First-in-Human clinical study in late 2025, propelling the compound from research into actual patient care.

Eilean's Commitment to Cancer Research

Founded with a mission to confront resistance-driven malignancies, Eilean Therapeutics is at the forefront of cancer treatment innovation. Their proprietary hybrid AI/ML-enabled drug design platform facilitates significant advancements in the identification and refinement of unique cancer therapies. Currently, Eilean's oncology portfolio features multiple independent programs, including selective, brain-penetrating CDK2 and CDK4 inhibitors specifically tailored for cancers characterized by CCNE1 amplification and CCND1 amplification, respectively.

The design of each program is strategically aligned to promote synergy and tandem action with complementary treatment methodologies, particularly in the landscape of targeted and immune-oncology treatments effectively countering resistance to existing therapies.

For more details on Eilean Therapeutics and its trailblazing advancements in cancer therapeutics, visit www.eileanther.com.

Media Contact

For additional inquiries, reach out to:
Amy Burd, PhD
Chief Scientific Officer
Eilean Therapeutics, Inc.
Email: [email protected]